Hybrid immunoglobulins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5714147
SERIAL NO

08451848

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
GENENTECH, INC.SOUTH SAN FRANCISCO, CA2055

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Capon, Daniel J San Mateo, CA 62 4135
Lasky, Laurence A Sausalito, CA 36 1928

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Hoechst Aktiengesellschaft (1)
* 5359035 Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) 65 1992
 
GENENTECH, INC. (1)
* 5116964 Hybrid immunoglobulins 559 1989
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (5)
* 2003/0219,436 Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein 18 2002
* 2003/0203,837 IG/OB fusions and uses thereof 2 2003
* 2004/0077,022 Modified peptides as therapeutic agents 19 2003
* 2006/0057,135 Mucosal vascular addressins and uses thereof 1 2005
8633305 Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules 5 2011
 
WYETH LLC (12)
7704503 Use of IL-17F in diagnosis and therapy of airway inflammation 0 2006
7910105 Methods for treating and preventing fibrosis 0 2006
* 2006/0257,403 Methods for treating and preventing fibrosis 8 2006
* 2008/0064,856 Methods for reducing protein aggregation 13 2007
7744890 Methods and compositions with reduced opalescence 0 2007
7731946 ) cell development and function 4 2007
* 2008/0269,132 USE OF LOW TEMPERATURE AND/OR LOW PH IN CELL CULTURE 47 2008
* 2009/0142,806 INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 0 2008
8058407 Purification of acidic proteins using ceramic hydroxyapatite chromatography 15 2009
* 2010/0113,751 PURIFICATION OF ACIDIC PROTEINS USING CERAMIC HYDROXYAPATITE CHROMATOGRAPHY 4 2009
* 2011/0039,780 PLATELET GLYCOPROTEIN IB ALPHA VARIANT FUSION POLYPEPTIDES AND METHODS OF USE THEREOF 0 2009
* 2011/0033,451 INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 1 2010
 
ALEXION PHARMACEUTICALS, INC. (1)
9266939 Compositions comprising natriuretic peptides and methods of use thereof 0 2011
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (3)
7368114 Fusion protein including of CD4 0 2002
* 2004/0265,306 Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4 0 2004
* 2009/0285,815 IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION 0 2008
 
EMERGENT PRODUCTIVE DEVELOPMENT SEATTLE, LLC. (1)
8409577 Single chain multivalent binding proteins with effector function 5 2007
 
OLERUP SSP AB (3)
7897328 Blood group antigens of different types for diagnostic and therapeutic applications 0 2007
* 2007/0224,652 Blood Group Antigens of Different Types for Diagnostic and Therapeutic Applications 1 2007
8404456 Blood group antigens of different types for diagnostic and therapeutic applications 0 2011
 
AMYLIN PHARMACEUTICALS, INC. (1)
7718400 Methods of increasing lean tissue mass using OB protein compositions 0 2007
 
ITERATIVE THERAPEUTICS, INC. (6)
8163289 Methods and compositions involving polymeric immunoglobulin fusion proteins 0 2008
* 2008/0292,704 Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins 1 2008
7897729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors 3 2008
* 2009/0117,133 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS 6 2008
8986698 Method of using fusion proteins 0 2011
9127063 Nucleic acids related to fusion proteins 0 2013
 
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (2)
9499606 Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules 0 2013
9695229 Compositions of, and methods for, alpha-1 antitrypsin Fc fusion molecules 0 2014
 
The Rockefeller University (9)
6429290 OB polypeptides, modified forms and derivatives 9 1995
6471956 Ob polypeptides, modified forms and compositions thereto 7 1995
6350730 OB polypeptides and modified forms as modulators of body weight 6 1995
6309853 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof 31 1995
* 6124448 Nucleic acid primers and probes for the mammalian OB gene 1 1995
* 6048837 OB polypeptides as modulators of body weight 30 1995
7544492 OB polypeptides, modified forms and derivatives 3 2000
7994301 Modulators of body weight, corresponding nucleic acids and proteins 0 2009
8173793 Nucleic acids encoding modulators of body weight 0 2009
 
MERCK SHARP & DOHME CORP. (6)
7713521 MCP1 fusions 1 2006
* 2007/0036,750 MCP1 fusions 4 2006
7972591 Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions 1 2009
8282914 Method for treating atherosclerosis by administering human MCP1 fusions 1 2011
* 2011/0206,669 MCP1 FUSIONS 0 2011
8524217 MCP1-Ig fusion variants 1 2011
 
RECOPHARMA AB (12)
8034351 Mucin fusion polypeptide vaccines, compositions and methods of use thereof 3 2003
* 2004/0002,585 Mucin fusion polypeptide vaccines, compositions and methods of use thereof 5 2003
7638323 Fusion proteins and methods of producing same 0 2003
* 2004/0137,580 Fusion proteins and methods of producing same 4 2003
7658919 adhesion and infection 0 2005
* 2006/0177,463 Compositions and methods for inhibiting H. pylori adhesion and infection 0 2005
* 2007/0184,063 Production of Proteins Carrying Oligomannose or Human-Like Glycans in Yeast and Methods of Use Thereof 2 2007
* 2007/0184,065 Compositions and Methods for Inhibiting Viral Adhesion 1 2007
* 2008/0096,806 Compositions and methods for inhibiting microbial adhesion 0 2007
* 2009/0181,041 Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof 4 2008
* 2009/0280,134 COMPOSITIONS AND METHODS FOR INHIBITING TOXIN A FROM CLOSTRIDIUM DIFFICILE 1 2009
* 2009/0280,104 COMPOSITIONS AND METHODS FOR INHIBITING SHIGA TOXIN AND SHIGA-LIKE TOXIN 0 2009
 
YALE UNIVERSITY (6)
6924359 Neovascular-targeted immunoconjugates 0 2000
7858092 Neovascular-targeted immunoconjugates 2 2005
* 2005/0214,298 Neovascular-targeted immunoconjugates 0 2005
8071104 Neovascular-targeted immunoconjugates 1 2010
* 2011/0117,114 Neovascular-Targeted Immunoconjugates 0 2010
8388974 Neovascular-targeted immunoconjugates 0 2011
 
BROWN UNIVERSITY (1)
* 2007/0117,981 Rhodium quinonoid catalysts 0 2006
 
MILLENNIUM PHARMACEUTICALS, INC. (6)
7803904 Mucosal vascular addressing and uses thereof 0 1996
* 2002/0147,314 MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF 5 1997
* 2002/0172,679 Treatment of inflammatory bowel disease by inhibiting binding and/or signalling through alpha4beta7 and its ligands and MAdCAM 7 2002
8277808 Mucosal vascular addressins and uses thereof 0 2007
* 2007/0178,089 Mucosal vascular addressins and uses thereof 0 2007
9663579 Formulation for anti-α4β7 antibody 0 2016
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (8)
* 2010/0015,642 B7-H1 AND SURVIVIN IN CANCER 3 2007
* 2009/0215,084 B7-H1 AND B7-H4 IN CANCER 4 2007
8039589 B7-DC variants 7 2007
* 2009/0176,317 Soluble B7-H1 5 2008
* 2011/0020,325 METHODS FOR REDUCING GRANULOMATOUS INFLAMMATION 4 2009
8747833 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer 3 2011
8273864 Nucleic acid molecules encoding B7-DC variants 2 2011
8460927 B7-H1 antibodies and method of use 3 2011
 
ABSORBER AB (1)
* 2004/0001,844 Lewis Y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof 1 2003
 
TRUBION PHARMACEUTICALS (3)
7754209 Binding constructs and methods for use thereof 20 2003
* 2007/0059,306 B-cell reduction using CD37-specific and CD20-specific binding molecules 27 2006
* 2010/0279,932 BINDING CONSTRUCTS AND METHODS FOR USE THEREOF 14 2010
 
MICROMET AG (2)
7332168 Composition for the elimination of autoreactive B-cells 0 2001
* 2004/0072,749 Composition for the elimination of autoreactive b-cells 5 2003
 
TRUBION PHARMACEUTICALS, INC. (7)
* 2005/0238,646 Binding domain-immunoglobulin fusion proteins 75 2005
* 2005/0202,012 Binding domain-immunogloubulin fusion proteins 27 2005
* 2005/0202,023 Binding domain-immunoglobulin fusion proteins 70 2005
* 2005/0202,534 Binding domain-immunoglobulin fusion proteins 73 2005
* 2005/0186,216 Binding domain-immunoglobulin fusion proteins 31 2005
* 2005/0180,970 Binding domain-immunoglobulin fusion proteins 29 2005
* 2005/0175,614 Binding domain-immunoglobulin fusion proteins 70 2005
 
HANMI SCIENCE CO., LTD. (4)
7736653 Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier 16 2004
7737260 Protein complex using an immunoglobulin fragment and method for the preparation thereof 18 2004
* 2010/0255,014 Protein Complex Using An Immunoglobulin Fragment and Method For The Preparation Thereof 1 2010
8110665 Pharmaceutical composition comprising an immunoglobulin FC region as a carrier 13 2010
 
WYETH (14)
* 2003/0133,936 CD25markers and uses thereof 13 2002
* 2004/0016,010 IL-21 receptor knockout animal and methods of use thereof 21 2003
7314623 Methods and compositions for modulating T helper (Th) cell development and function 11 2003
* 2004/0136,954 Methods and compositions for modulating T helper (Th) cell development and function 8 2003
7618632 Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies 3 2004
* 2005/0014,224 GITR ligand and GITR ligand-related molecules and antibodies and uses thereof 14 2004
7727535 Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof 0 2004
* 2005/0089,888 Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof 0 2004
* 2006/0039,902 Antagonizing interleukin-21 receptor activity 52 2005
* 2006/0140,935 Platlet glycoprotein Ib alpha fusion polypeptides and methods of use thereof 0 2005
* 2006/0093,614 Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof 0 2005
* 2011/0033,483 SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION 13 2007
* 2008/0241,098 ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY 16 2007
* 2010/0080,809 GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF 1 2009
 
GENECRAFT, INC. (1)
* 2004/0058,445 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB 28 2002
 
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC (4)
* 2003/0133,939 Binding domain-immunoglobulin fusion proteins 152 2002
7754208 Binding domain-immunoglobulin fusion proteins 22 2002
* 2009/0214,539 B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES 23 2009
* 2011/0223,164 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 6 2011
 
ARNASON, BARRY G. (2)
7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors 10 2002
* 2003/0161,826 Polymeric immunoglobulin fusion proteins that target low-affinity fcyreceptors 42 2002
 
THE JOHNS HOPKINS UNIVERSITY (7)
8053414 Methods of using B7-DC molecules to induce or enhance an immune response 7 2007
8053558 Dendritic cell co-stimulatory molecules 7 2007
* 2008/0226,662 Dendritic cell co-stimulatory molecules 15 2007
8153595 B7-DC variants immunogenic compositions and methods of use thereof 5 2008
* 2009/0042,292 B7-DC Variants 10 2008
8445447 B7-DC variants immunogenic compositions and methods of use thereof 0 2012
9370565 Dendritic cell co-stimulatory molecules 0 2013
 
GENENTECH, INC. (14)
* 6994856 ErbB4 receptor-specific neuregulin related ligands and uses therefor 2 1998
6696290 ErbB2 and ErbB4 Chimeric Heteromultimeric Adhesins 33 1999
7101851 IgE receptor antagonists 2 2001
7084109 FVIIa antagonists 14 2002
* 2003/0119,727 FVIIa antagonists 6 2002
7164002 FVIIa antagonists 0 2003
7659368 ErbB2 and ErbB3 chimeric heteromultimer adhesins 1 2003
* 2004/0138,417 Chimeric heteromultimer adhesins 15 2003
7662585 ErbB4 receptor-specific neuregulin related ligands and uses therefor 0 2004
* 2005/0136,467 ErbB4 receptor-specific neuregulin related ligands and uses therefor 0 2005
7846453 Methods of stimulating ErbB4 receptor phosphorylation 0 2006
* 2007/0081,994 Chimeric Heteromultimer Adhesins 8 2006
* 2007/0190,058 METHOD FOR TREATING INTRAOCULAR NEOVASCULAR DISEASES 6 2007
8226935 ErbB2 and ErbB3 chimeric heteromultimer receptors 0 2009
 
APTEVO RESEARCH AND DEVELOPMENT LLC (15)
7829084 Binding constructs and methods for use thereof 17 2003
* 2005/0136,049 Binding constructs and methods for use thereof 67 2003
8106161 Binding domain-immunoglobulin fusion proteins 5 2005
* 2005/0202,028 Binding domain-immunoglobulin fusion proteins 72 2005
8333966 CD37 immunotherapeutics and uses thereof 5 2009
* 2011/0171,208 CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF 10 2009
9101609 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof 0 2009
8147835 Binding domain-immunoglobulin fusion proteins 5 2009
* 2010/0034,820 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 11 2009
8197810 Binding domain-immunoglobulin fusion proteins 3 2010
8188237 Binding domain-immunoglobulin fusion proteins 3 2010
* 2011/0105,729 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 11 2010
* 2011/0091,461 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 11 2010
8853366 Binding domain-immunoglobulin fusion proteins 0 2012
9005612 Binding domain-immunoglobulin fusion proteins 4 2012
 
AMGEN INC. (37)
6660843 Modified peptides as therapeutic agents 234 1999
7166707 Modified peptides as therapeutic agents 16 2003
7189827 Modified peptides as therapeutic agents 18 2003
* 2004/0053,845 Modified peptides as therapeutic agents 3 2003
* 2004/0071,712 Modified peptides as therapeutic agents 2 2003
7186810 Modified peptides as therapeutic agents 4 2003
7169905 Modified peptides as therapeutic agents 3 2003
* 2004/0087,778 Modified peptides as therapeutic agents 20 2003
6936439 OB fusion protein compositions and methods 12 2003
8044174 Thrombopoietic compounds 3 2004
* 2005/0080,014 Thrombopoietic compounds 0 2004
7208577 Methods of increasing lean tissue mass using OB protein compositions 2 2005
* 2005/0176,107 Methods of increasing lean tissue mass using OB protein compositions 1 2005
7112659 OB fusion protein compositions and methods 4 2005
7442778 Modified Fc molecules 62 2005
* 2006/0140,934 Modified Fc molecules 16 2005
9145450 Thrombopoietic compounds 0 2006
* 2006/0234,307 Modified peptides as therapeutic agents 1 2006
8008453 Modified Fc molecules 10 2006
8080254 OB fusion protein compositions and methods 0 2006
* 2007/0020,284 OB fusion protein compositions and methods 0 2006
* 2007/0049,532 Modified peptides as therapeutic agents 1 2006
* 2007/0224,193 METHODS OF INCREASING LEAN TISSUE MASS USING OB PROTEIN COMPOSITIONS 0 2007
7750127 Modified Fc molecules 16 2008
7750128 Modified Fc molecules 18 2008
7662931 Modified Fc molecules 35 2008
7655764 Modified Fc molecules 20 2008
7655765 Modified Fc molecules 20 2008
7645861 Modified Fc molecules 18 2008
* 2009/0022,744 Modified Fc molecules 7 2008
* 2009/0012,272 Modified Fc molecules 7 2008
7994117 Thrombopoietic compounds 3 2009
* 2009/0186,822 Thrombopoietic Compounds 0 2009
9114175 Modified Fc molecules 0 2011
8748571 Thrombopoietic compounds 3 2011
8618044 Thrombopoietic compounds 3 2012
9534032 Thrombopoietic compounds 0 2014
 
Cavit Sciences, Inc (1)
* 2007/0161,546 Methods and compositions for treatment of cancer 1 2006
 
MEDIMMUNE, LLC (1)
8709416 Compositions of PD-1 antagonists and methods of use 8 2011
 
Genetics Institute, LLC (9)
7189400 Methods of treatment with antagonists of MU-1 7 2001
6991796 Platlet glycoprotein IBα fusion polypeptides and methods of use thereof 0 2002
7198789 Methods and compositions for modulating interleukin-21 receptor activity 10 2002
* 2003/0108,549 Methods and compositions for modulating interleukin-21 receptor activity 8 2002
7049128 Platelet glycoprotein Ib.alpha. fusion polypeptides and methods of use thereof 0 2003
7705123 MU-1, member of the cytokine receptor family 2 2007
* 2008/0167,241 MU-1, MEMBER OF THE CYTOKINE RECEPTOR FAMILY 3 2007
* 2009/0148,427 PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF USE THEREOF 0 2008
7994292 MU-1, member of the cytokine receptor family 0 2010
* Cited By Examiner